Ziopharm Oncology Announces Pricing of Public Offering of Common Stock
All securities in the offering are being sold by Ziopharm.
Ziopharm intends to use the net proceeds from the offering, together with its current cash and cash equivalents, for progressing its clinical programs towards commercialization, working capital needs and other general corporate purposes.
Jefferies is acting as sole book-running manager for the offering. Cantor is acting as lead manager for the offering.
The offering is expected to close on or about
The securities are being offered pursuant to an effective shelf registration statement that was previously filed with the
When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free from
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding Ziopharm’s expectations regarding the completion of the offering. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Ziopharm, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in Ziopharm’s Quarterly Report on Form 10-Q for the period ended
VP, Investor Relations and Corporate Communications
Source: ZIOPHARM Oncology Inc